Cassava Sciences (SAVA)

• Market cap: $116M
• 1 day: 2.55%
• 5 days: -8.71%
• 1 month: -43.95%
• 3 months: -91.07%
• 6 months: -87.83%
• Year to date: -89.25%
• 1 year: -89.68%
• 5 years: -5.86%
• 10 years: -76.26%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.

Employees: 29

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

146% more capital invested

Capital invested by funds: $167M [Q2] → $411M (+$244M) [Q3]

56% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 32

50% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 24

8% more funds holding

Funds holding: 146 [Q2] → 158 (+12) [Q3]

1.04% more ownership

Funds ownership: 28.16% [Q2] → 29.2% (+1.04%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

56% less call options, than puts

Call options by funds: $81M | Put options by funds: $183M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $116 4,713% upside
• Avg. target: $116 4,713% upside
• High target: $116 4,713% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Vernon Bernardino 31% 1-year accuracy 18 / 59 met price target

4,713% upside $116

Neutral Downgraded

26 Nov 2024